Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 73–84 of 202 trials
Not yet recruitingATTR (transthyretin)
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) (opens on ClinicalTrials.gov)
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Eidos Therapeutics, a BridgeBio company
No study locations listed yet
NCT07116473Updated 11 August 2026
RecruitingNot specified
Cardiovascular Multimodality Imaging Study (opens on ClinicalTrials.gov)
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular…
- Study
- Observational (registry, imaging)
- Sponsor
- Montefiore Medical Center
Recruiting in: United States
NCT06610019Updated 10 August 2026
Not yet recruitingAL (light chain)
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) (opens on ClinicalTrials.gov)
Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by the production of misfolded immunoglobulin light chains that deposit in organs and lead…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Recruiting in: China
NCT07751471Updated 7 August 2026
Not yet recruitingAL (light chain)
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis (opens on ClinicalTrials.gov)
This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Case Comprehensive Cancer Center
Recruiting in: United States
NCT07524634Updated 5 August 2026
RecruitingATTR (transthyretin)
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant (opens on ClinicalTrials.gov)
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Recruiting in: ArgentinaAustraliaBelgiumBrazil+20
NCT06563895Updated 4 August 2026
RecruitingAL (light chain)
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). (opens on ClinicalTrials.gov)
The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Shanghai Zhongshan Hospital
Recruiting in: China
NCT07638683Updated 3 August 2026
Enrolling by invitationATTR (transthyretin)
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 (opens on ClinicalTrials.gov)
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of…
- Study
- Observational (registry, imaging)
- Sponsor
- Intellia Therapeutics
Recruiting in: FranceNew ZealandSwedenUnited Kingdom
NCT05697861Updated 3 August 2026
RecruitingATTR (transthyretin)
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis (opens on ClinicalTrials.gov)
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Study
- Interventional (treatment)
- Phase
- Phase 4
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Recruiting in: United States
NCT07695701Updated 29 July 2026
Not yet recruitingNot specified
Detection of Cardiac Amyloidosis Using Right Ventricular Sensing Amplitude in Patients With Left Ventricular Hypertrophy (opens on ClinicalTrials.gov)
This multicenter prospective study aims to evaluate the diagnostic performance of right ventricular sensing amplitude measured during cardiac implantable electronic device (CIED) implantation (pacemaker…
- Study
- Interventional (treatment)
- Sponsor
- Assistance Publique – Hôpitaux de Paris
No study locations listed yet
NCT07734285Updated 29 July 2026
RecruitingAL (light chain)
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis (opens on ClinicalTrials.gov)
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis. Participants will…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Peking University People's Hospital
Recruiting in: China
NCT07335887Updated 28 July 2026
RecruitingATTR (transthyretin)
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis (opens on ClinicalTrials.gov)
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- University of Tennessee Graduate School of Medicine
Recruiting in: United States
NCT05951816Updated 24 July 2026
RecruitingAL (light chain)
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis (opens on ClinicalTrials.gov)
This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Recruiting in: China
NCT07151690Updated 23 July 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 7 November 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.